Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways... Show more
RVMD saw its Momentum Indicator move above the 0 level on July 10, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for RVMD just turned positive on July 11, 2025. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
RVMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
RVMD moved below its 50-day moving average on June 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RVMD crossed bearishly below the 50-day moving average on June 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RVMD entered a downward trend on July 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RVMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.433) is normal, around the industry mean (18.109). P/E Ratio (0.000) is within average values for comparable stocks, (58.647). RVMD's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (270.773).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology
1 Day | |||
---|---|---|---|
FOREX / NAME | Price $ | Chg $ | Chg % |
HKDAUD | 0.20 | 0.00 | +0.41% |
Hong Kong Dollar - Australian Dollar | |||
NFEAX | 17.45 | 0.04 | +0.23% |
Columbia Large Cap Growth Opp A | |||
RGREX | 9.03 | 0.02 | +0.22% |
Invesco Global Real Estate R | |||
CMCRX | 43.30 | 0.02 | +0.05% |
Calvert US Mid Cap Core Rspnb Idx R6 | |||
USDAUD | 1.54 | -0.00 | -0.01% |
United States Dollar - Australian Dollar |
A.I.dvisor indicates that over the last year, RVMD has been loosely correlated with OCUL. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RVMD jumps, then OCUL could also see price increases.
Ticker / NAME | Correlation To RVMD | 1D Price Change % | ||
---|---|---|---|---|
RVMD | 100% | -1.92% | ||
OCUL - RVMD | 57% Loosely correlated | -0.44% | ||
CRNX - RVMD | 56% Loosely correlated | -5.78% | ||
ERAS - RVMD | 55% Loosely correlated | +4.17% | ||
IDYA - RVMD | 52% Loosely correlated | -2.26% | ||
NRIX - RVMD | 52% Loosely correlated | -7.28% | ||
More |